Micafungin

Candidemia, prophylaxis of Esophageal candidiasis, Aspergillosis + 10 more
Treatment
11 FDA approvals
20 Active Studies for Micafungin

What is Micafungin

MicafunginThe Generic name of this drug
Treatment SummaryMicafungin is a medication used to treat fungal infections. It works by blocking the production of an essential component of the cell wall of fungi, called 1,3-beta-D-glucan.
Mycamineis the brand name
Micafungin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mycamine
Micafungin
2005
23

Approved as Treatment by the FDA

Micafungin, otherwise known as Mycamine, is approved by the FDA for 11 uses including Candidiasis and Systemic candidiasis .
Candidiasis
Systemic candidiasis
Meningoencephalitis
prophylaxis of Candida Infections
Bone Marrow Transplant
Candidemia
Peritonitis
Yeast Infection
Meningoencephalitis
Esophageal Candidiasis
Abscess

Effectiveness

How Micafungin Affects PatientsMicafungin, formerly known as FK463, is a medicine that fights off fungal infections. It works by blocking an enzyme in the fungus that helps build its cell wall. Depending on how much of the medicine is taken, it can either stop the fungus from growing (fungistatic) or kill it (fungicidal). Micafungin can be taken with other medicines, such as HIV drugs and transplant medicines.
How Micafungin works in the bodyMicafungin prevents fungi from forming cell walls by blocking a compound, called beta-1,3-D-glucan synthase, that the fungi needs to build the walls. This compound isn't found in humans, so our cells are not affected.

When to interrupt dosage

The recommended quantity of Micafungin is contingent upon the identified condition, which may include Infections, Fungal, Candida (fungus) and Abscesses. The amount likewise varies as per the technique of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Intravenous) featured in the table beneath.
Condition
Dosage
Administration
prophylaxis of Esophageal candidiasis
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Aspergillosis
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
prophylaxis of moderate Pneumocystis pneumonia
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Yeast Infection
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
prophylaxis of Candida Infections
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
HIV Positive
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Abscess
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
HIV
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Esophageal Candidiasis
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Bone Marrow Transplant
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Peritonitis
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Meningoencephalitis
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Candidemia
, 50.0 mg, 100.0 mg, 20.0 mg/mL, 10.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL
, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Micafungin Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 16 known major drug interactions with Micafungin.
Common Micafungin Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Moderate
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Micafungin.
(S)-Warfarin
Moderate
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Micafungin.
4-hydroxycoumarin
Moderate
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Micafungin.
Acenocoumarol
Moderate
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Micafungin.
Clorindione
Moderate
The therapeutic efficacy of Clorindione can be increased when used in combination with Micafungin.
Micafungin Toxicity & Overdose RiskThe toxic dose of Diflucan for rats is 125mg/kg. In dogs, the toxic dose is higher than 200mg/kg. So far, no reports of overdose have been made. In clinical trials, adults have taken up to 8mg/kg of Diflucan per day with no severe side effects. The lowest dose that could be fatal to rats is 125mg/kg, which is 8.1 times the usual dose given to humans with esophageal candidiasis.

Micafungin Novel Uses: Which Conditions Have a Clinical Trial Featuring Micafungin?

459 active experiments are being conducted to assess the suitability of Micafungin for Candida (fungus), Abscesses and Peritonitis treatment.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV Positive
0 Actively Recruiting
Esophageal Candidiasis
0 Actively Recruiting
Aspergillosis
0 Actively Recruiting
Peritonitis
0 Actively Recruiting
prophylaxis of Candida Infections
0 Actively Recruiting
Bone Marrow Transplant
27 Actively Recruiting
Not Applicable, Phase 2, Early Phase 1, Phase 1
Yeast Infection
0 Actively Recruiting
Meningoencephalitis
0 Actively Recruiting
Abscess
0 Actively Recruiting
prophylaxis of Esophageal candidiasis
0 Actively Recruiting
prophylaxis of moderate Pneumocystis pneumonia
0 Actively Recruiting
Candidemia
4 Actively Recruiting
Phase 3, Phase 2

Patient Q&A Section about micafungin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long do you take micafungin?

"In patients who were successfully treated with micafungin, the average duration of therapy was 15 days, with a range of 10 to 30 days."

Answered by AI

What is micafungin used for?

"Micafungin is used to treat candidemia, acute disseminated candidiasis, candida peritonitis and abscess, and esophageal candidiasis."

Answered by AI

Is micafungin an antibiotic?

"Micafungin sodium is an antifungal medication used to treat and prevent infections caused by the Candida fungus."

Answered by AI

What kind of drug is micafungin?

"This medication can be used to treat a variety of fungal infections and to prevent fungal infections in patients who are going through a stem cell transplant. Micafungin works by stopping the growth of fungi and belongs to a class of drugs known as echinocandins."

Answered by AI

Clinical Trials for Micafungin

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Micafungin clinical trials? We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.Go to Trials
Have you considered Micafungin clinical trials? We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Micafungin clinical trials? We made a collection of clinical trials featuring Micafungin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security